Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jiangsu Hengrui Shifts From Generic Supplier To Innovative Company; Analysts See Shades Of Takeda In Transformation

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Jiangsu Hengrui Medicine Co. Ltd. seeks to transform itself from a generic company to an innovative one and tap into overseas markets. The move has prompted Chinese analysts to draw comparisons to the business models of Japan's largest pharma and to predict that Jiangsu Hengrui could become China's version of Takeda Pharmaceutical Co. Ltd.

You may also be interested in...



China’s Hengrui In-Licenses AMD Antibody Program From X-Body Biosciences

Hengrui becomes the first Chinese manufacturer to in-license an early stage MAb from a Western biopharma as it looks to develop an age-related macular degeneration therapy that could compete with Novartis/Roche’s Lucentis and Bayer/Regeneron’s Eylea.

China’s Hengrui In-Licenses AMD Antibody Program From X-Body Biosciences

Hengrui becomes the first Chinese manufacturer to in-license an early stage MAb from a Western biopharma as it looks to develop an age-related macular degeneration therapy that could compete with Novartis/Roche’s Lucentis and Bayer/Regeneron’s Eylea.

Chinese Local Pharmas See Innovative Products As Future Growth Driver - China Healthcare Investment Conference

BEIJING - Fueled by the Chinese government's latest five-year plan that will promote innovation and increase exports of finished products, Chinese domestic companies are increasing their R&D efforts to ensure future growth, companies said during the second annual China Healthcare Investment conference March 23

Related Content

UsernamePublicRestriction

Register

ID1124690

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel